Related Experiment Video
Updated: Dec 5, 2025

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
Bioequivalence and Evaluation Parameters Based on the Pharmacodynamics of Miglitol in Healthy Volunteers
Juan Yan1,2, Xiao-Min Li1, Yan-Xin Zhang1
1Phase Ⅰ Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Abstract:
The aim of this study was to explore the bioequivalence of miglitol based on pharmacodynamic properties. The study was performed as a single-dose, randomized, open-label, 3-period, 3-way crossover trial over a 7-day washout period. Forty-eight subjects were randomly assigned into 3 groups: (1) miglitol test formulation/sucrose coadministration, (2) miglitol reference formulation/sucrose coadministration, and (3) sucrose administration alone. Serum glucose concentrations were measured by the hexokinase detection method. The peak serum glucose concentration (Cmax ) and the area under the serum glucose concentration-time curve through 4 hours (AUC0-4h ) were used as the main pharmacodynamic parameters to evaluate bioequivalence. The 90% confidence intervals for the geometric mean ratios of Cmax and AUC0-4h were 94.81%-101.07% and 98.82%-100.72%, respectively, which were all within the bioequivalence range of 80.00%-125.00%. The test and reference formulations of miglitol were pharmacodynamically bioequivalent during the trial.
Related Concept Videos
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioequivalence Data: Statistical Interpretation
Bioequivalence: Overview
Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence studies: Biowaivers

